The round is led by Lumen Ventures with the participation of a|impact, GCM Group, Padda Health and Finalca
Rome-based healthtech startup that offers an ecosystem of AI-powered solutions for genetic analysis and clinical decision support for diseases, GenomeUp has raised €1.1 million for its seed round led by Lumen Ventures. Other participants in this round include a|impact, GCM Group, Padda Health, and existing investors. The capital raised will be used to expand the team and consolidate activities in Italy. GenomeUp’s mission is to be a global reference platform to support clinical decision-making for hospitals, laboratories, research centers, and pharmaceuticals to accelerate diagnosis times, improve patient care and provide knowledge for health prevention, all in less than 24h. Based on these assumptions, the founders decided to evolve the startup and transform it into a Italian Benefit Corporation following the purpose of common benefit by acting responsibly, sustainably and transparently towards stakeholders, people, communities, the territory and the environment.
GenomeUp was launched in 2018 by LVenture Group through its acceleration program LUISS EnLabs and with the first pre-seed investment.
“GenomeUp has developed several bioinformatics tools and protocols to make data and metadata – today big health data – traceable, accessible, interoperable and reusable, necessary for researchers and clinicians who want to give an answer to the millions of people who face the odyssey of the diagnosis of a genetic disease, even more so if rare”, says Simone Gardini CEO and Founder.
To date, GenomeUp has signed scientific and commercial partnerships with hospitals and international genetic diagnostics companies, with over ten scientific publications in global medical-scientific journals, in collaboration with European research centers, marking an absolute record considering the young age of the startup and team.